These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

851 related items for PubMed ID: 21575016

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.
    Lancet; 2011 Apr 30; 377(9776):1506-13. PubMed ID: 21529928
    [Abstract] [Full Text] [Related]

  • 8. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.
    Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O'Malley SS.
    Alcohol Clin Exp Res; 2009 Feb 30; 33(2):350-6. PubMed ID: 19053979
    [Abstract] [Full Text] [Related]

  • 9. Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months.
    Lee JD, Grossman E, Huben L, Manseau M, McNeely J, Rotrosen J, Stevens D, Gourevitch MN.
    J Subst Abuse Treat; 2012 Dec 30; 43(4):458-62. PubMed ID: 22985676
    [Abstract] [Full Text] [Related]

  • 10. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
    O'Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, Rounsaville BJ, Wu R.
    Alcohol Clin Exp Res; 2007 Apr 30; 31(4):625-34. PubMed ID: 17374042
    [Abstract] [Full Text] [Related]

  • 11. Early treatment response in alcohol dependence with extended-release naltrexone.
    Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM.
    J Clin Psychiatry; 2008 Feb 30; 69(2):190-5. PubMed ID: 18348601
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
    Lucey MR, Silverman BL, Illeperuma A, O'Brien CP.
    Alcohol Clin Exp Res; 2008 Mar 30; 32(3):498-504. PubMed ID: 18241321
    [Abstract] [Full Text] [Related]

  • 14. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.
    Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK.
    Alcohol Clin Exp Res; 2001 Nov 30; 25(11):1634-47. PubMed ID: 11707638
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
    Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME.
    Arch Gen Psychiatry; 2005 Jan 30; 62(1):37-45. PubMed ID: 15630071
    [Abstract] [Full Text] [Related]

  • 16. Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts.
    Finigan MW, Perkins T, Zold-Kilbourn P, Parks J, Stringer M.
    J Subst Abuse Treat; 2011 Oct 30; 41(3):288-93. PubMed ID: 21696912
    [Abstract] [Full Text] [Related]

  • 17. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
    Malone M, McDonald R, Vittitow A, Chen J, Obi R, Schatz D, Tofighi B, Garment A, Kermack A, Goldfeld K, Gold H, Laska E, Rotrosen J, Lee JD.
    Contemp Clin Trials; 2019 Jun 30; 81():102-109. PubMed ID: 30986535
    [Abstract] [Full Text] [Related]

  • 18. Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study.
    Lukas SE, Lowen SB, Lindsey KP, Conn N, Tartarini W, Rodolico J, Mallya G, Palmer C, Penetar DM.
    Neuroimage; 2013 Sep 30; 78():176-85. PubMed ID: 23571420
    [Abstract] [Full Text] [Related]

  • 19. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
    Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH, VA Cooperative Study #425 Study Group.
    Alcohol Clin Exp Res; 2007 Apr 30; 31(4):555-63. PubMed ID: 17374034
    [Abstract] [Full Text] [Related]

  • 20. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
    Feeney GF, Connor JP, Young RM, Tucker J, McPherson A.
    Alcohol Alcohol; 2006 Apr 30; 41(3):321-7. PubMed ID: 16467406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.